Congress is considering a bill that would expand the federal government’s ability to pursue the war on drugs, granting new power to the Attorney General to set federal drug policy.
The bipartisan legislation, sponsored by powerful committee chairs in both chambers of Congress, would allow the Attorney General to unilaterally outlaw certain unregulated chemical compounds on a temporary basis. It would create a special legal category for these drugs, the first time in nearly 50 years that the CSA has been expanded in this way. And it would set penalties, potentially including mandatory minimum sentences, for the manufacture and distribution of these drugs.
“This bill provides federal law enforcement with new tools to ensure those peddling dangerous drugs, which can be lethal, are brought to justice,” said Senator Dianne Feinstein, D-Calif., who is sponsoring the Senate version with Senator Chuck Grassley, R-Iowa, in an emailed statement. “It also explicitly exempts simple possession from any penalties, instead targeting those who manufacture and traffic these drugs and opioids.”
The bill, introduced last week and known as the Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, now moves to a hearing of the Senate Judiciary Committee, which Grassley chairs and where Feinstein is the top-ranking Democrat. The House bill is listed as H.R. 2851.
Under current law, all psychoactive substances are placed in one of five “Schedules” designating the drugs’ risk of abuse and medical potential. Schedule 1 is the most restrictive, reserved for drugs like LSD, heroin and marijuana. Schedule 5 is the least restrictive category, which includes medications like low-dose codeine cough syrup.
Illicit drug manufacturers wishing to avoid these designations often make subtle changes to a drug’s chemistry, creating slightly different, and hence legal, substances which produce similar psychoactive effects in users.
“Illegal drug traffickers and importers are able to circumvent the existing scheduling regime by altering a single atom or molecule of a currently controlled substance in a laboratory, thereby creating a substance that is lawful, but often highly dangerous, addictive and even deadly,” said Senators Dianne Feinstein and Chuck Grassley in a fact sheet about the Senate version of the bill.
SITSA would create a new schedule, Schedule A, for substances that are chemically similar to already-regulated drugs. The Attorney General would be able to place new compounds in Schedule A for a period of up to five years. Critics say this amounts to giving the Attorney General the power to unilaterally write federal drug policy.
The bill “gives the Attorney General a ton of power in terms of scheduling drugs and pursuing penalties,” said Michael Collins of the Drug Policy Alliance, a drug policy reform group. “This is a giant step backwards and really it’s doing the bidding of Jeff Sessions as he tries to escalate the war on drugs.”
Under current policy, an Attorney General may only temporarily schedule a substance for up to two years, and only then after demonstrating the drug’s “history and current pattern of abuse; the scope, duration and significance of abuse; and what, if any, risk there is to the public health.”
The new bill extends the temporary scheduling duration to five years for Schedule A substances, and eliminates the requirement for analyzing the drug’s abuse record and its potential risk to public health.
The bill is partially a response to a spike in overdose deaths from the powerful synthetic opiate fentanyl and chemically similar drugs, in recent years. Fentanyl’s “uncontrolled synthetic analogues have come to represent the deadly convergence of the synthetic drug problem and the opioid epidemic,” Feinstein and Grassley write. The bill adds 13 synthetic analogs of fentanyl to Schedule A immediately.
But reform advocates are worried that the bill’s language could be used to justify bans on all manner of substances that are not particularly lethal or dangerous. The drug known as kratom is one particular area of concern. Experts say the risks of using the drug are “remarkably low,” and people who take it say it’s helped them quit using alcohol, opiates and other, much deadlier substances.
Because the drug’s primary chemicals act in a similar fashion to some opioids, advocates fear that that the new bill would allow the Department of Justice to outlaw the drug, as it tried, unsuccessfully, to do last year.
Some experts think that the fentanyl epidemic is proving to be so lethal that it may be worthwhile to experiment with different legislative approaches, even if they come with drawbacks.
“The fentanyls are so awful that I think it is entirely reasonable to try a fentanyl supply control strategy that has only a very modest chance of success,” said Jonathan Caulkins of Carnegie-Mellon University.
He added that it might be wise, however, to include automatic sunset provisions to such strategies in case they prove ineffective.